As of the start of this week, the European Union Artificial Intelligence Act’s rules around transparency in AI-generated content are now enforceable.
The act has significant implications for marketers in pharma and beyond. Under the new code of practice, any providers or deployers of AI-generated content in the EU must clearly label that content as such, using markings visible to both humans and machines.
The rules apply to chatbots and conversational AI tools, as well as AI-generated text, images, videos and audio, including deepfakes and text that didn’t undergo human review or editorial control but pertains to matters of public interest.
AI-generated content published prior to the effective date of Aug. 2 has until December to comply with the new rules, while any content published from now on must already be in compliance. Companies that don’t abide by the code could face penalties of up to €15 million or 3% of their annual gross revenue.
According to the EU, the guidelines are meant to “foster trust and integrity in the information ecosystem,” enabling people to make more informed decisions and “calibrate their trust and reliance on AI and avoid misinformation or deception.”
The EU’s focus on improving trust amid the explosion of AI content and tools echoes the ongoing conversation in pharma media about improving HCP and patient trust—and the new rules could represent a powerful opportunity for brands to strengthen that trust.
One recent...
Create your FREE account to continue reading and explore more expert insights on Pharma Media.
✅ Free. Fast. No commitment.